







Metformin is a first-line drug in the pharmacotherapy 
of type 2 diabetes mellitus (DM). Apart from the low 
cost, good efficacy, and beneficial effects on body 
weight, the relatively safe adverse effect profile has 
justified the widespread use of metformin [1, 2]. Several 
studies have reported association of vitamin B12 
deficiency in type 2 diabetes patients treated with 
metformin [3—5]. Metformin does, however, induce 
vitamin B12 malabsorption, which may increase the risk 
of developing vitamin B12 deficiency — a clinically 
important and treatable condition. In addition, met -
formin treatment has been reported to be associated 
with decreased folate concentration, although the 
mechanism of this effect has not been elucidated. 
Finally, decreases in both folate and vitamin B12 
concentrations might, in turn, result in an increase in 
homocysteine concentrations, an independent risk 
factor for cardiovascular disease, especially among 
individuals with type 2 DM [6, 7]. 
All current evidence on vitamin B12 deficiency in 
metformin treatment comes from short term studies 
[8—10]. No long term, placebo controlled data on the 
effects of metformin on concentrations of vitamin B12 in 
patients with type 2 DM have been reported. In addition, 
placebo controlled data on the effects of metformin on 
homocysteine concentrations in type 2 diabetes are 
sparse, and again no long term data are available.
Clinically, vitamin B12 deficiency could lead to altered 
mental status, megaloblastic anemia, and neurological 
damage [11]. Peripheral neuropathy due to vitamin B12 
deficiency may be confused with diabetic peripheral 
neuropathy or may contribute to the aggravation of 
diabetic peripheral neuropathy [12]. The progression of 
neurologic damage due to vitamin B12 deficiency can 
be stopped by early detection and treatment with 
cobalamin supplementation [13]. However, if this 
occurrence is misdiagnosed as diabetic neuropathy, 
permanent neurological damage may occur [14]. This 
study was done to further explore this question.
Aim of the study — to study the prevalence of 
vitamin B12 deficiency and the factors associated with 
it in patients with type 2 diabetes mellitus who were 
treated with metformin.
MATERIALS AND METHODS
The patients were recruited from the endocrinology 
outpatient department of a tertiary care center from 
August 2018 to December 2018, after taking informed 
consent. 
Patients were defined as type 2 DM with an age at 
diagnosis above 30 years. Pregnancy, pernicious ane -
mia, malabsorption syndrome, gastrointestinal surgery, 
autoimmune thyroid disease, chronic hepatitis, chronic 
kidney disease stage 4 and above, chronic alcohol 
abuse, and the use of oral/parenteral vitamin B12 or 
multivitamin supplements were exclusion criteria.
An observational study was conducted from August 
2018 to December 2018. The study was approved by 
the Univetsity Ethical Committee. 
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A total of 53 patients with type 2 DM (group 1, 
n = 35, receiving metformin and group 2, n = 25, never 
treated with metformin) from the endocrinology clinic 
in Chernivtsi were studied.
Group 1 consisted of patients with type 2 DM with 
ongoing treatment with metformin with duration of 
metformin use > 6 months while second group 
consisted of patients with type 2 DM who had never 
received metformin. 
History about diabetes onset, dose, and duration of 
metformin usage as well as recent (within 3 months) 
glycated hemoglobin (HbA1c) was obtained from Centre 
records. The Centre records, patient’s prescriptions, and 
medicines were also searched for prescription of any 
vitamin B12-containing supplements and patients were 
shown a list of commonly available multivitamins 
containing vitamin B12 and were asked about their use 
at any time in the past. 
Vitamin B12 estimation was done by competitive 
chemiluminescent enzyme immunoassay on Immulite 
analyzer using commercial kits from Siemens Healthcare 
Diagnostics Inc., New York, USA. The calibration range 
of this assay was 197—771 pg/ml. Vitamin B12 deficiency 
was defined as levels below 190 pg/ml. 
Statistical analysis was performed using Statistical 
Package for Social Sciences SPSS version 14 (SPSS Inc., 
Chicago, IL, USA). Continuous variables were described 
as mean and standard deviation. The categorical 
variables were stated as proportions or percentages. 
The comparison between the first group and second 
group was done with Student’s t-test for continuous 
variables and Chi-square test for categorical variables. 
Linear regression analyses were carried out to study 
the effect of duration since the diagnosis of diabetes, 
use of metformin, and duration of metformin use on 
serum vitamin B12 levels. P < 0.05 was considered 
statistically significant.
RESULTS
A total of 60 patients with type 2 DM (group 1, 
n = 35, receiving metformin and group 2, n = 25, never 
treated with metformin) from the endocrinology clinic 
in Chernivtsi were studied. Serum Vitamin B12 levels 
were measured in all patients. The mean age of the 
study population was 51.9 ± 9.3 years. Table 1 shows 
the baseline characteristics of patients with type 2 DM. 
The two groups were comparable except for duration 
of DM which was significantly greater in the first group. 
Duration of metformin use was 26.2 ± 5.4 months 
(range 6—140 months). Daily dose of metformin was 
839.2 ± 53.1 mg (range 500—2500 mg). The cumula -
tive dose of metformin was 970.8 ± 517.2 g (range 
85—10,590 g).
The serum mean unadjusted vitamin B12 levels were 
239.6 ± 37.4 pg/ml in the first group and 293.6 ± 42.3 
pg/ml in the second group (p = 0.37).
The mean duration of DM was longer in the first 
group as compared to the second group (6.7 ± 1.1 
years vs. 1.9 ± 0.6 years, p < 0.01). Vitamin B12 deficiency 
was present in 16 (45.7 %) of the first group and in 
6 (24.0 % of the second group (p = 0.04).
On univariate linear regression analysis with vitamin 
B12 levels as the dependent variable and metformin use 
(no and yes) as the predictor variable, metformin use 
was associated with a 8.7 ± 3.9 pg/ml (p = 0.73) lower 
vitamin B12 level. On univariate linear regression analysis 
with vitamin B12 levels as the dependent variable and 
duration of DM as the predictor variable, vitamin B12 
levels were 12.2 ± 3.0 pg/ml (95 % CI 6.4—18.0, p < 0.001) 
higher for every 1 year increase in the duration of DM.
To further study the association of vitamin B12 levels 
and duration of DM, we performed a stratified analysis. 
Figure 1 shows the box plot of serum vitamin B12 with 
duration of DM categorized into newly diagnosed 
(0—1 year), 1—5 years, and > 5 years. Serum vitamin B12 
levels were higher by 41.4 pg/ml in patients with DM of 
1—5 years compared to those with recently diagnosed 
diabetes (p = 0.41). Serum vitamin B12 levels were higher 
by 119.4 pg/ml in patients with duration of DM > 5 years 
compared to those with recently diagnosed diabetes 
(p < 0.02). Similarly, serum vitamin B12 levels were 
77.1  pg/ml higher in > 5 years DM duration group 
compared to 1—5 year duration of DM group (p = 0.03).
On univariate linear regression analysis with vitamin 
B12 levels as the dependent variable and duration of 
Table 1
Baseline characteristics of patients with type 2 DM
Variable Group 1, n = 35
Group 2, 
n = 25 P
Age, years 52.7 ± 3.4 49.4 ± 3.1 0.47
Sex, n (%)
Male 16 (45.7) 11 (44.0) 0.34
Female 19 (54.3) 14 (56.0)
Duration of DM, years 6.7 ± 1.1 1.9 ± 0.6 < 0.01
BMI, kg/m2 29.3 ± 2.4 29.3 ± 2.4 0.23
HbAlc, % 7.9 ± 1.5 7.8 ± 1.4 0.30
DM — diabetes mellitus, BMI — body mass index, 
HbAlc — glycated hemoglobin
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metformin use as the predictor variable, duration of 
metformin use predicted a 0.8 ± 0.4 pg/ml (p = 0.05) 
lower Vitamin B12 levels for every 1 month increase in 
the duration of metformin use. On stratifying duration 
of metformin use into no metformin use, 0—1 years, 
1—5 years, and more than 5 years, it was found that a 
20.1 pg/ml (p = 0.64) and 37.3 pg/ml lower serum 
vitamin B12 concentration was observed in individuals 
with a 0—1 years and 1—5 year duration of metformin 
use, respectively, compared with the group which had 
not received metformin. 
In contrast, the serum concentration of vitamin B12 
was higher by 45.4 pg/ml (p = 0.27) in individuals who 
had received metformin for more than 5 years compa -
red to those who had never received metformin. To 
understand the interplay of duration of DM and 
metformin use on serum Vitamin B12 levels, a stratified 
analysis was carried out. A multivariate linear regression 
analysis with serum vitamin B12 levels as the dependent 
variable and metformin use (no/yes) and duration of 
DM (stratified as 1—5 years and > 5 years) as predictor 
variables were done to adjust for the duration of DM. 
In this analysis, metformin use group was associated 
with a 87.3 ± 37.1 pg/ml (p = 0.03) lower serum vitamin 
B12 levels. The serum vitamin B12 levels were 104.9 ± 
42.0 pg/ml (p = 0.02) higher in the 1—5 year duration 
of DM group while they were 192.3 ± 48.9 pg/ml 
(p < 0.01) higher in > 5 year duration of DM group. 
DISCUSSION
The present study involving 60 patients with type 
2 DM (35 metformin and 25 without metformin) 
showed lower vitamin B12 levels with metformin use, 
when adjusted for duration since diagnosis of diabetes, 
which is consistent with other studies published earlier 
[1—7]. Without adjusting for duration of DM, there was 
neither a significant difference in serum vitamin B12 
levels nor in the prevalence of vitamin B12 deficiency. 
However, the prevalence of vitamin B12 deficiency in 
patients on metformin in our study is higher than that 
reported in literature [4—6, 15]. 
An interesting finding from our study is the sta -
tistically significant rise in vitamin B12 with increasing 
duration of DM. In a cross-sectional study from the US 
comprising 1621 patients with type 2 DM (575 on 
metformin and 1046 not on metformin) and 6867 
persons without diabetes, the DM without metformin 
group had the lowest prevalence of vitamin B12 deficiency 
(2.4 %) as compared to 5.8 % in the diabetes on 
metformin group and the 3.3 % in the group without 
diabetes [3]. We did make an active effort to exclude 
patients who had been given vitamin B12-containing 
supplements for any indication (review of available 
medical records was done, and patients were asked 
about the use of vitamin B12-containing multivitamin 
supplements), but these preparations are available over 
the counter, and we cannot be sure that patients had 
never taken these medications earlier. In addition, the 
higher vitamin B12 levels with greater duration of DM 
were seen in the second group also who were not at the 
risk of metformin-related vitamin B12 deficiency (as they 
never received metformin) and hence are less likely to 
have received vitamin B12 treatment.
The limitation of our study is that we did not measure 
functional markers of vitamin B12 deficiency (serum 
homocysteine and serum methylmalonic acid levels) 
which may better reflect the status of vitamin B12 levels 
in the body as compared to serum vitamin B12 levels. In 
addition, our sample size was small. The strength of this 
study is that the second group included only those 
patients who had never taken metformin. The reason for 
choosing such a group was to exclude a possible long-
term effect of metformin use on vitamin B12 status. 
Vitamin B12 is stored in the liver and several years may 
pass before the stores are depleted and detectable 
vitamin B12 deficiency manifests. Thus, including patients 
with a history of metformin use in the no metformin 
group is a potential confounder which we excluded in 
this study.
CONCLUSIONS
Metformin use was associated with a significantly 
lower serum vitamin B12 levels when adjusted for 
duration of diabetes. 
Figure 1. Vitamin B12 levels and duration of type 2 DM (0—1, 
0—5 years and > 5 years)
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Serum vitamin B12 levels were higher by 41.4 pg/ml 
in patients with DM of 1—5 years compared to those 
with recently diagnosed diabetes (p = 0.41). Serum 
vitamin B12 levels were higher by 119.4 pg/ml in 
patients with duration of DM > 5 years compared to 
those with recently diagnosed diabetes (p < 0.02). 
Similarly, serum vitamin B12 levels were 77.1 pg/ml 
higher in > 5 years DM duration group compared to 
1—5 year duration of DM group (p = 0.03).
Further study of the impact of duration of diabetes 
on serum vitamin B12 levels and of functional markers 
of vitamin B12 deficiency on hematological and 
neurological parameters will be interesting.
Джерела фінансування — відсутні. Гонорар за напи-
сання рукопису від комерційних організацій чи інших 
зацікавлених сторін автор не отримував.
Конфлікт інтересів — відсутній.
Етичні аспекти. Дослідження розглянуто Комі те -
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ABSTRACT
Vitamin B12 levels in metformin-treated 
type 2 diabetes patients
I. V. Pankiv
Bukovinian State Medical University, Chernivtsi
Background. Metformin is the most widely used 
oral antihyperglycaemic drug, but it may lower B12 
status, which could have important clinical implications. 
There are limited data about the effect of metformin 
use on serum vitamin B12 levels in type 2 diabetes 
mellitus (DM) patients. 
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Aim. To study serum Vitamin B12 levels in patients 
with type 2 diabetes mellitus who were receiving 
metformin and compared them to those never treated 
with metformin. 
Materials and methods. A total of 60 patients with 
type 2 DM (group 1, n = 35, receiving metformin and 
group 2, n = 25, never treated with metformin) from 
the endocrinology clinic in Chernivtsi were studied. 
Serum vitamin B12 levels were measured in all patients. 
Results and discussion. The serum vitamin B12 
levels were 239.6 ± 37.4 pg/ml in metformin group and 
293.6 ± 42.3 pg/ml in the no metformin group (p = 
0.37). When adjusted for duration of DM, metformin 
use was associated with a 57.2 ± 7.3 pg/ml (p = 0.03) 
lower serum vitamin B12 levels. Serum vitamin B12 levels 
were higher by 41.4 pg/ml in patients with DM of 1—5 
years compared to those with recently diagnosed 
diabetes (p = 0.41). Serum vitamin B12 levels were 
higher by 119.4 pg/ml in patients with duration of DM 
> 5 years compared to those with recently diagnosed 
diabetes (p < 0.02). Similarly, serum vitamin B12 levels 
were 77.1 pg/ml higher in > 5 years DM duration group 
compared to 1—5 year duration of DM group (p = 
0.03). Serum vitamin B12 levels for the entire cohort 
were higher by 11.8 ± 1.7 pg/ml (p < 0.01) for every 
1 year increase in the DM duration. 
Conclusions. Metformin use was associated with a 
lower serum vitamin B12 levels when adjusted for 
duration of DM. Increasing duration of DM was 
associated with higher serum vitamin B12 levels.
Key words: type 2 diabetes mellitus, metformin, 
vitamin B12 levels.
РЕЗЮМЕ
Вміст вітаміну В12 у хворих 
на цукровий діабет 2-го типу
І. В. Паньків
Буковинський державний медичний університет, Чернівці
Вступ. Метформін залишається найбільш вико-
ристовуваним пероральним антигіперглікемічним 
препаратом, однак при цьому він може знижувати 
рівень вітаміну B12, що може мати важливі клінічні 
наслідки. Наявні обмежені дані про вплив застосу-
вання метформіну на рівень вітаміну B12 у сироватці 
крові у хворих на цукровий діабет 2-го типу (ЦД2).
Мета роботи — вивчити рівень вітаміну B12 
у сироватці крові у пацієнтів із цукровим діабетом 
2 типу, які отримували метформін, та порівняти їх із 
пацієнтами, які ніколи не лікувалися метформіном.
Матеріали та методи. Під спостереженням 
перебували 60 пацієнтів із ЦД2 (група 1, n = 35, які 
отримували метформін, та група 2, n = 25, які ніколи 
не лікувались метформіном) з Чернівецького 
обласного ендокринологічного центру. Рівень віта-
міну B12 у сироватці крові вимірювали у всіх пацієн-
тів. Результати. Рівень вітаміну B12 у сироватці крові 
становив (239,6 ± 37,4) пг/мл у першій групі та 
(293,6 ± 42,3) пг/мл у другій групі (р = 0,37). Після 
скоригування за тривалістю ЦД2, використання 
метформіну було пов’язано з нижчим рівнем вітамі-
ну B12 у сироватці крові на (57,2 ± 7,3) пг/мл (р = 
0,03). Рівень вітаміну B12 у сироватці крові був біль-
шим на 41,4 пг/мл у пацієнтів із тривалістю ЦД2 від 
одного до п’яти років порівняно з тими, у кого діа-
бет був нещодавно діагностований (р = 0,41). Рівень 
вітаміну B12 у сироватці крові був більшим на 119,4 
пг/мл у пацієнтів із тривалістю ЦД2 > 5 років порів-
няно з пацієнтами з недавно діагностованим діа-
бетом (р < 0,02). Анало гічно, рівень вітаміну B12 у 
сироватці крові був на 77,1 пг/мл вище при трива-
лості ЦД2 понад 5 років порівняно з хворими з 
тривалістю ЦД2 1—5 років (р = 0,03). Рівень вітамі-
ну B12 у сироватці крові для всієї когорти був вищим 
на (11,8 ± 1,7) пг/мл (95 % ДІ 6,3—17,0, р < 0,01) за 
кожен рік збільшення тривалості ЦД2. Висновки. 
Застосування метформіну пов’язано з нижчим рів-
нем вітаміну B12 у сироватці крові, що залежало від 
тривалості цукрового діабету.
Ключові слова: цукровий діабет 2-го типу, мет-
формін, вітамін B12.
РЕЗЮМЕ
Содержание витамина В12 
у больных сахарным диабетом 2-го типа
И. В. Панькив
Буковинский государственный медицинский 
университет, Черновцы
Вступление. Метформин остается наиболее 
используемым пероральным антигипергликемичес-
ким препаратом, однако при этом он может снижать 
уровень витамина В12, что может иметь важные кли-
нические последствия. Имеются ограниченные 
данные о влиянии применения метформина на уро-
вень витамина В12 в сыворотке крови у больных 
сахарным диабетом 2-го типа (СД2). 
Цель работы — изучить уровень витамина В12 
в сыворотке крови у пациентов с сахарным диабе-
том 2-го типа, получавших метформин, и сравнить 
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их с пациентами, которые никогда не лечились мет-
формином. 
Материалы и методы. Под наблюдением находи-
лись 60 пациентов с СД2 (группа 1, n = 35, получав-
ших метформин и группа 2, n = 25, которые никогда 
не лечились метформином) из Черновицкого област-
ного эндокринологического центра. Уровень витами-
на В12 в сыворотке крови измеряли у всех пациентов. 
Результаты. Уровень витамина В12 в сы воротке крови 
составил (239,6 ± 37,4) пг/мл в первой группе и (293,6 
± 42,3) пг/мл во второй группе (р = 0,37). После кор-
рекции по продолжительности СД2 использование 
метформина было связано с более низким уровнем 
витамина В12 в сыворотке крови на (57,2 ± 7,3) пг/мл 
(р = 0,03). Уровень витамина В12 в сыворотке крови 
был больше на 41,4 пг/мл у пациентов с длительнос-
тью СД2 от одного до пяти лет по сравнению с теми, 
у кого диабет был недавно диагностирован (р = 0,41). 
Уровень витамина В12 в сыворотке крови был больше 
на 119,4 пг/мл у пациентов с длительностью СД2 
свыше 5 лет по сравнению с пациентами с недавно 
диагностированным диабетом (р < 0,02). Аналогично, 
уровень витамина В12 в сыворотке крови был на 77,1 
пг/мл выше при продолжительности СД2 более 5 лет 
по сравнению с больными с длительностью СД2 1—5 
лет (р = 0,03). Уровень витамина В12 в сыворотке 
крови для всей когорты был выше на (11,8 ± 1,7) пг/
мл (95 % ДИ 6,3—17,0, р < 0,01) на каждый год увели-
чения продолжительности СД2. Выводы. Применение 
метформина связано с низким уровнем витамина В12 
в сыворотке крови, что зависело от продолжитель-
ности сахарного диабета.
Ключевые слова: сахарный диабет 2-го типа, 
метформин, витамин В12.
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